Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 307-317 , June 2010

Neuroblastoma: Therapeutic strategies for a clinical enigma

  • Shakeel Modak

      Affiliations

    • Corresponding Author InformationCorresponding author. Address: Department of Pediatrics, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, Unites States. Tel.: +1 212 639 7623; fax: +1 212 717 3695.
    • ,
  • Nai-Kong V. Cheung

References 

  1. Yamamoto K, Hayashi Y, Hanada R, et al. Mass screening and age-specific incidence of neuroblastoma in Saitama Prefecture. Jpn J Clin Oncol. 1995;13:2033–2038
  2. Woods WG, Gao RN, Shuster JJ, et al. Screening of infants and mortality due to neuroblastoma. N Engl J Med. 2002;346:1041–1046
  3. Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer. 1997;79:2028–2035
  4. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Cheung NK. Neuroblastoma in adolescents and adults: the Memorial Sloan-Kettering experience. Med Pediatr Oncol. 2003;41:508–515
  5. Schwab M, Alitalo K, Klempnauer K-H, et al. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and neuroblastoma tumor. Nature. 1983;305:245–248
  6. Shimada H, Stram DO, Chatten J, et al. Identification of subsets of neuroblastomas by combined histopathologic and N-myc analysis. J Natl Cancer Inst. 1995;87:1470–1476
  7. Brodeur G, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging and response to treatment. J Clin Oncol. 1993;11:1466–1477
  8. Monclair T, Brodeur GM, Ambros PF, et al. The international neuroblastoma risk group (INRG) staging system: an INRG task force report. J Clin Oncol. 2009;27:298–303
  9. Cohn SL, Pearson AD, London WB, et al. The international neuroblastoma risk group (INRG) classification system: an INRG task force report. J Clin Oncol. 2009;27:289–297
  10. Brodeur GM, Maris JM. Neuroblastoma. Princ Pract Pediatr Oncol, 2006.
  11. Kushner BH, Cheung NK, LaQuaglia MP, et al. International neuroblastoma staging system stage 1 neuroblastoma: a prospective study and literature review. J Clin Oncol. 1996;14:2174–2180
  12. Hero B, Simon T, Spitz R, et al. Localized infant neuroblastomas often show spontaneous regression: results of the prospective trials NB95-S and NB97. J Clin Oncol. 2008;26:1504–1510
  13. Cheung NKV, Kushner BH, LaQuaglia MP, et al. Survival from non-stage 4 neuroblastoma without cytotoxic therapy: an analysis of clinical and biologic markers. Eur J Cancer. 1997;33:2117–2121
  14. Kushner BH, Cheung NK, LaQuaglia MP, et al. Survival from locally invasive or widespread neuroblastoma without cytotoxic therapy. J Clin Oncol. 1996;14:373–381
  15. Bagatell R, Rumcheva P, London WB, et al. Outcomes of children with intermediate-risk neuroblastoma after treatment stratified by MYCN status and tumor cell ploidy. J Clin Oncol. 2005;23:8819–8827
  16. George RE, Li S, Medeiros-Nancarrow C, et al. High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol. 2006;24:2891–2896
  17. Berthold F, Boos J, Burdach S, et al. Myeloablative megatherapy with autologous 28 stem-cell rescue versus oral maintenance chemotherapy as consolidation treatment in patients with high-risk neuroblastoma: a randomised controlled trial. Lancet Oncol. 2005;6:649–658
  18. Matthay KK, Villablanca JG, Seeger RC, et al. Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children’s cancer group. N Engl J Med. 1999;341:1165–1173
  19. Laverdiere C, Cheung NK, Kushner BH, et al. Long-term complications in survivors of advanced stage neuroblastoma. Pediatr Blood Cancer. 2005;45:324–332
  20. De Bernardi B, Conte M, Mancini A, et al. Localized resectable neuroblastoma: results of the second study of the Italian cooperative group for neuroblastoma. J Clin Oncol. 1995;13:884–893
  21. Modak S, Kushner BH, LaQuaglia MP, Kramer K, Cheung NK. Management and outcome of stage 3 neuroblastoma. Eur J Cancer. 2009;45:90–98
  22. Matthay KK, Sather HN, Seeger RC, Haase GM, Denman Hammond G. Excellent outcome of stage II neuroblastoma is independent of residual disease and radiation therapy. J Clin Oncol. 1989;7:236–244
  23. Perez CA, Matthay KK, Atkinson JB, et al. Biologic variables in the outcome of stages I and II neuroblastoma treated with surgery as primary therapy: a children’s cancer group study. J Clin Oncol. 2000;18:18–26
  24. Maris JM, Hogarty MD, Bagatell R, Cohn SL. Neuroblastoma. Lancet. 2007;369:2106–2120
  25. Matthay KK, Perez C, Seeger RC, et al. Successful treatment of stage III neuroblastoma based on prospective biologic staging: a children’s cancer group study. J Clin Oncol. 1998;16:1256–1264
  26. Park JR, Villablanca JG, London WB, et al. Outcome of high-risk stage 3 neuroblastoma with myeloablative therapy and 13-cis-retinoic acid: a report from the children’s oncology group. Pediatr Blood Cancer. 2009;52:44–50
  27. Park JE, London W, Maris JM, et al. Prognostic markers for stage 3 neuroblastoma (NB): a report from the international neuroblastoma risk group (INRG) project. Proc ASCO, 2008.
  28. Attiyeh EF, London WB, Mosse YP, et al. Chromosome 1p and 11q deletions and outcome in neuroblastoma. N Engl J Med. 2005;353:2243–2253
  29. Bown N, Cotterill S, Lastowska M, et al. Gain of chromosome arm 17q and adverse outcome in patients with neuroblastoma. N Engl J Med. 1999;340:1954–1961
  30. De Bernardi B, Balwierz W, Bejent J, et al. Epidural compression in neuroblastoma: diagnostic and therapeutic aspects. Cancer Lett. 2005;228:283–299
  31. Sandberg DI, Bilsky MH, Kushner BH, et al. Treatment of spinal involvement in neuroblastoma patients. Pediatr Neurosurg. 2003;39:291–298
  32. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti-CD20) adjunctive therapy for opsoclonus–myoclonus syndrome. J Pediatr Hematol Oncol. 2006;28:585–593
  33. Pranzatelli MR, Tate ED, Travelstead AL, Longee D. Immunologic and clinical responses to rituximab in a child with opsoclonus–myoclonus syndrome. Pediatrics. 2005;115:e115–e119
  34. Bagatell R, Beck-Popovic M, London WB, et al. Significance of MYCN amplification in international neuroblastoma staging system stage 1 and 2 neuroblastoma: a report from the international neuroblastoma risk group database. J Clin Oncol. 2009;27:365–370
  35. Evans AE, Baum E, Chard R. Do infants with stage IV-S neuroblastoma need treatment?. Arch Disease Child. 1981;56:271–274
  36. Katzenstein HM, Bowman LC, Brodeur GM, et al. Prognostic significance of age, MYCN oncogene amplification, tumor cell ploidy, and histology in 110 infants with stage D(S) neuroblastoma: the pediatric oncology group experience – a pediatric oncology group study. J Clin Oncol. 1998;16:2007–2017
  37. Mora J, Cheung NK, Kushner BH, et al. Clinical categories of neuroblastoma are associated with different patterns of loss of heterozygosity on chromosome arm 1p. J Mol Diagn. 2000;2:37–46
  38. Spitz R, Hero B, Ernestus K, Berthold F. Deletions in chromosome arms 3p and 11q are new prognostic markers in localized and 4s neuroblastoma. Clin Cancer Res. 2003;9:52–58
  39. Schmidt ML, Lal A, Seeger RC, et al. Favorable prognosis for patients 12 to 18 months of age with stage 4 nonamplified MYCN neuroblastoma: a children’s cancer group study. J Clin Oncol. 2005;23:6474–6480
  40. George RE, London WB, Cohn SL, et al. Hyperdiploidy plus nonamplified MYCN confers a favorable prognosis in children 12 to 18 months old with disseminated neuroblastoma: a pediatric oncology group study. J Clin Oncol. 2005;23:6466–6473
  41. Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9:247–256
  42. De Bernardi B, Nicolas B, Boni L, et al. Disseminated neuroblastoma in children older than one year at diagnosis: comparable results with three consecutive high-dose protocols adopted by the Italian co-operative group for neuroblastoma. J Clin Oncol. 2003;21:1592–1601
  43. Cheung NK, Heller G. Chemotherapy dose intensity correlates strongly with response, median survival and median progression-free survival in metastatic neuroblastoma. J Clin Oncol. 1991;9:1050–1058
  44. Cheung NK, Kushner BH, LaQuaglia M, et al. N7: a novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Med Pediatr Oncol. 2001;36:227–230
  45. Kushner BH, Kramer K, LaQuaglia MP, Modak S, Yataghene K, Cheung NK. Reduction from seven to five cycles of intensive induction chemotherapy in children with high-risk neuroblastoma. J Clin Oncol. 2004;22:4888–4892
  46. Shamberger RC, Allarde-Segundo A, Kozakewich HP, Grier HE. Surgical management of stage III and IV neuroblastoma: resection before or after chemotherapy?. J Pediatr Surg. 1991;26:1113–1117[discussion 7-8]
  47. Wolden SL, Gollamudi SV, Kushner BH, et al. Local control with multimodality therapy for stage 4 neuroblastoma. Int J Radiat Oncol Biol Phys. 2000;46:969–974
  48. La Quaglia MP. Surgical management of neuroblastoma. Semin Pediatr Surg. 2001;10:132–139
  49. Wolden SL, Barker CA, Kushner BH, et al. Brain-sparing radiotherapy for neuroblastoma skull metastases. Pediatr Blood Cancer. 2008;50:1163–1168
  50. Kushner BH, Wolden S, LaQuaglia MP, et al. Hyperfractionated low-dose radiotherapy for high-risk neuroblastoma after intensive chemotherapy and surgery. J Clin Oncol. 2001;19:2821–2828
  51. Kletzel M, Katzenstein HM, Haut PR, et al. Treatment of high-risk neuroblastoma with triple-tandem high-dose therapy and stem-cell rescue: results of the Chicago pilot II study. J Clin Oncol. 2002;20:2284–2292
  52. Klingebiel T, Bader P, Bares R, et al. Treatment of neuroblastoma stage 4 with 131I-meta-iodo-benzylguanidine, high-dose chemotherapy and immunotherapy. A pilot study. Eur J Cancer. 1998;34:1398–1402
  53. Matthay KK, Seeger RC, Reynolds CP, et al. Allogeneic versus autologous purged bone marrow transplantation for neuroblastoma: a report from the childrens cancer group. J Clin Oncol. 1994;12:2382–2389
  54. Kushner BH, Kramer K, Modak S, et al. Topotecan, thiotepa, and carboplatin for neuroblastoma: failure to prevent relapse in the central nervous system. Bone Marrow Transplant. 2006;37:271–276
  55. Modak S, Cheung NK. Disialoganglioside directed immunotherapy of neuroblastoma. Cancer Invest. 2007;25:67–77
  56. Hakomori S. Tumor-associated carbohydrate antigens defining tumor malignancy: basis for development of anti-cancer vaccines. Adv Exp Med Biol. 2001;491:369–402
  57. Kushner BH, Cheung IY, Kramer K, Modak S, Cheung NK. High-dose cyclophosphamide inhibition of humoral immune response to murine monoclonal antibody 3F8 in neuroblastoma patients: broad implications for immunotherapy. Pediatr Blood Cancer. 2007;48:430–434
  58. Kushner BH, Kramer K, Modak S, Cheung NK. Camptothecin analogs (irinotecan or topotecan) plus high-dose cyclophosphamide as preparative regimens for antibody-based immunotherapy in resistant neuroblastoma. Clin Cancer Res. 2004;10:84–87
  59. Cheung NK, Kushner BH, Cheung IY, et al. Anti-G(D2) antibody treatment of minimal residual stage 4 neuroblastoma diagnosed at more than 1 year of age. J Clin Oncol. 1998;16:3053–3060
  60. Gilman AL, Ozkaynak MF, Matthay KK, et al. Phase I study of ch14.18 with granulocyte-macrophage colony-stimulating factor and interleukin-2 in children with neuroblastoma after autologous bone marrow transplantation or stem-cell rescue: a report from the children’s oncology group. J Clin Oncol. 2009;27:85–91
  61. Cheung NK, Saarinen UM, Neely JE, Landmeier B, Donovan D, Coccia PF. Monoclonal antibodies to a glycolipid antigen on human neuroblastoma cells. Cancer Res. 1985;45:2642–2649
  62. Xu H, Hu J, Cheung NK. Induction of tumor cell death by anti-GD2 monoclonal antibodies: requirement of antibody Fc and a long residence time (slow k off). J Clin Oncol ASCO Annu Meet Proc. 2007;25:13507
  63. Munn DH, Cheung NK. Interleukin-2 enhancement of monoclonal antibody-mediated cellular cytotoxicity (ADCC) against human melanoma. Cancer Res. 1987;47:6600–6605
  64. Munn DH, Cheung NK. Antibody-dependent antitumor cytotoxicity by human monocytes cultured with recombinant macrophage colony-stimulating factor. Induction of efficient antibody-mediated antitumor cytotoxicity not detected by isotope release 31 assays. J Exp Med. 1989;170:511–526
  65. Kushner BH, Cheung NK. GM-CSF enhances 3F8 monoclonal antibody-dependent cellular cytotoxicity against human melanoma and neuroblastoma. Blood. 1989;73:1936–1941
  66. Kushner BH, Cheung NK. Absolute requirement of CD11/CD18 adhesion molecules, FcRII and the phosphatidylinositol-linked FcRIII for monoclonal antibody-mediated neutrophil antihuman tumor cytotoxicity. Blood. 1992;79:1484–1490
  67. Hong F, Yan J, Baran JT, et al. Mechanism by which orally administered beta-1, 3-glucans enhance the tumoricidal activity of antitumor monoclonal antibodies in murine tumor models. J Immunol. 2004;173:797–806
  68. Kushner B, Kramer K, Modak S, Cheung NK. Anti-GD2 monoclonal antibody 3F8 plus granulocyte macrophage colony stimulating factor for primary refractory neuroblastoma in bone marrow. Proc ASCO. 2007;25:9502
  69. Gillies SD, Lo K-M, Wesolowski J. High-level expression of chimeric antibodies using adapted cDNA variable region cassettes. J Immunol Methods. 1989;125:191–202
  70. Barker E, Mueller BM, Handgretinger R, Herter M, Yu AL, Reisfeld RA. Effect of a chimeric anti-ganglioside GD2 antibody on cell-mediated lysis of human neuroblastoma cells. Cancer Res. 1991;51:144–149
  71. Barker E, Reisfeld RA. A mechanism for neutrophil-mediated lysis of human neuroblastoma cells. Cancer Res. 1993;53:362–367
  72. Mueller BM, Romerdahl CA, Gillies SD, Reisfeld RA. Enhancement of antibody-dependent cytotoxicity with a chimeric anti-GD2 antibody. J Immunol. 1990;144:1382–1386
  73. Simon T, Hero B, Faldum A, et al. Consolidation treatment with chimeric anti-GD2-antibody ch14.18 in children older than 1 year with metastatic neuroblastoma. J Clin Oncol. 2004;22:3549–3557
  74. Yu A, Gilman A, Ozkaynak M, et al. A phase III randomized trial of the chimeric anti-GD2 antibody ch14.18 with GM-CSF and IL2 as immunotherapy following dose intensive chemotherapy for high-risk neuroblastoma: Children’s Oncology Group (COG) study ANBL0032. Proc ASCO, 2009:abs 10067z.
  75. Thiele CJ, Reynolds CP, Israel MA. Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma. Nature. 1985;313:404–406
  76. Linney E. Retinoic acid receptors: transcription factors modulating gene regulation, development, and differentiation. Curr Top Dev Biol. 1992;27:309–350
  77. Kohler JA, Imeson J, Ellershaw C, Lie SO. A randomized trial of 13-cis retinoic acid in children with advanced neuroblastoma after high-dose therapy. Br J Cancer. 2000;83:1124–1127
  78. Villablanca JG, Krailo MD, Ames MM, Reid JM, Reaman GH, Reynolds CP. Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the children’s oncology group (CCG 09709). J Clin Oncol. 2006;24:3423–3430
  79. Kramer K, Kushner B, Heller G, Cheung NK. Neuroblastoma metastatic to the central nervous system. The Memorial Sloan-Kettering cancer center experience and a literature review. Cancer. 2001;91:1510–1519
  80. Matthay KK, Brisse H, Couanet D, et al. Central nervous system metastases in neuroblastoma: radiologic, clinical, and biologic features in 23 patients. Cancer. 2003;98:155–165
  81. Kramer K, Kushner B, Modak S, et al. Compartmental intrathecal radioimmunotherapy: results for treatment for metastatic CNS neuroblastoma. J Neurooncol 2010 (in press).
  82. Kramer K, Humm JL, Souweidane MM, et al. Phase I study of targeted radioimmunotherapy for leptomeningeal cancers using intra-Ommaya 131-I-3F8. J Clin Oncol. 2007;25:5465–5470
  83. Lau L, Tai D, Weitzman S, Grant R, Baruchel S, Malkin D. Factors influencing survival in children with recurrent neuroblastoma. J Pediatr Hematol Oncol. 2004;26:227–232
  84. Kushner B, Kramer K, Modak S, Cheung NK. Sensitivity of surveillance studies for detecting aysmtomatic and unsuspected relapse of high-risk neuroblastoma. J Clin Oncol. 2009;27:1041–1046
  85. Langler A, Christaras A, Abshagen K, Krauth K, Hero B, Berthold F. Topotecan in the treatment of refractory neuroblastoma and other malignant tumors in childhood – a phase-II-study. Klin Padiatr. 2002;214:153–156
  86. Garaventa A, Luksch R, Biasotti S, et al. A phase II study of topotecan with vincristine and doxorubicin in children with recurrent/refractory neuroblastoma. Cancer. 2003;98:2488–2494
  87. Kramer K, Kushner BH, Cheung NK. Oral topotecan for refractory and relapsed neuroblastoma: a retrospective analysis. J Pediatr Hematol Oncol. 2003;25:601–605
  88. Wagner LM, Crews KR, Iacono LC, et al. Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin Cancer Res. 2004;10:840–848
  89. Vassal G, Giammarile F, Brooks M, et al. A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Societe Francaise d’Oncologie Pediatrique (SFOP) and the United Kingdom children cancer study group (UKCCSG). Eur J Cancer. 2008;44:2453–2460
  90. Kushner BH, Kramer K, Modak S, Cheung NK. Irinotecan plus temozolomide for relapsed or refractory neuroblastoma. J Clin Oncol. 2006;24:5271–5276
  91. Fox E, Maris JM, Widemann BC, et al. A phase I study of ABT-751, an orally bioavailable tubulin inhibitor, administered daily for 21 days every 28 days in pediatric patients with solid tumors. Clin Cancer Res. 2008;14:1111–1115
  92. Kushner BH, Kramer K, Cheung NK. Phase II trial of the anti-G(D2) monoclonal antibody 3F8 and granulocyte-macrophage colony-stimulating factor for neuroblastoma. J Clin Oncol. 2001;19:4189–4194
  93. Cheung NK, Modak S. Oral (1→3),(1→4)-beta-D-glucan synergizes with antiganglioside GD2 monoclonal antibody 3F8 in the therapy of neuroblastoma. Clin Cancer Res. 2002;8:1217–1223
  94. Cheung NK, Modak S, Vickers A, Knuckles B. Orally administered beta-glucans enhance anti-tumor effects of monoclonal antibodies. Cancer Immunol Immunother. 2002;51:557–564
  95. Modak S, Koehne G, Vickers A, O’Reilly RJ, Cheung NK. Rituximab therapy of lymphoma is enhanced by orally administered (1→3),(1→4)-d-beta-glucan. Leuk Res. 2005;29:679–683
  96. Modak S, Kushner B, Kramer K, Vickers A, Cheung NK. Combination of anti-GD2 antibody 3F8 and barley-derived (1→3), 1→4) Β-D-glucan: phase I study in patients with resistant neuroblastoma advances in neuroblastoma research. Proc ANR 2006:abs 326.
  97. Gillies SD, Reilly EB, Lo KM, Reisfeld RA. Antibody-targeted interleukin-2 stimulates T-cell killing of autologous tumor cells. Proc Natl Acad Sci USA. 1992;89:1428–1432
  98. Hank JA, Surfus JE, Gan J, et al. Activation of human effector cells by a tumor reactive recombinant anti-ganglioside GD2 interleukin-2 fusion protein (ch14.18-IL2). Clin Cancer Res. 1996;2:1951–1959
  99. Pancook JD, Becker JC, Gillies SD, Reisfeld RA. Eradication of established hepatic human neuroblastoma metastases in mice with severe combined immunodeficiency by antibody-targeted interleukin-2. Cancer Immunol Immunother. 1996;42:88–92
  100. Osenga K, Hank J, Albertini MR, et al. A phase I trial of immunocytokine HU14.18-IL12 in children with recurrent or refractory neuroblastoma and other GD2 positive malignancies: a study of the children’s oncology group. Proc ISBTC, 2004:50.
  101. Shusterman S, London W, Gillies SA, et al. Anti-neuroblastoma activity of hu14.18-IL2 against minimal residual disease in a children’s oncology group phase II study. J Clin Oncol 2008;26 Suppl:Abs 3002.
  102. Yeh SD, Larson SM, Burch L, et al. Radioimmunodetection of neuroblastoma with iodine-131-3F8: correlation with biopsy, iodine-131-metaiodobenzylguanidine (MIBG) and standard diagnostic modalities. J Nucl Med. 1991;32:769–776
  103. Cheung NK, Pentlow K, Graham MC, Yeh SDJ, Finn RD, Larson SM. Radioimmunotherapy of human neuroblastoma using monoclonal antibody 3F8. In: Fifth international radiopharmaceutical dosimetry symposium. Oak Ridge, Tennessee: Oak Ridge Associated Universities; 1992. p. 95–112.
  104. Modak S, Cheung NK. Antibody-based targeted radiation to pediatric tumors. J Nucl Med. 2005;46(Suppl. 1):157S–163S
  105. Modak S, Chung J, Cheung NK. Targeting of vascular endothelial growth factor (VEGF) synergizes with 131I-3F8 in radioimmunotherapy of human neuroblastoma (abs accepted for presentation at AACR 2006). Proc AACR 2006; p. 135–6.
  106. Modak S, Cheung NK, Abramson SJ, Price AP. Lack of early bevacizumab-related skeletal radiographic changes in children with neuroblastoma. Pediatr Blood Cancer, 2008.
  107. Meli ML, Carrel F, Waibel R, et al. Anti-neuroblastoma antibody chCE7 binds to an isoform of L1-CAM present in renal carcinoma cells. Int J Cancer. 1999;83:401–408
  108. Shurin GV, Shurin MR, Bykovskaia S, Shogan J, Lotze MT, Barksdale EM. Neuroblastoma-derived gangliosides inhibit dendritic cell generation and function. Cancer Res. 2001;61:363–369
  109. Wolfl M, Batten WY, Posovszky C, Bernhard H, Berthold F. Gangliosides inhibit the development from monocytes to dendritic cells. Clin Exp Immunol. 2002;130:441–448
  110. Valteau-Couanet D, Leboulaire C, Maincent K, et al. Dendritic cells for NK/LAK activation: rationale for multicellular immunotherapy in neuroblastoma patients. Blood. 2002;100:2554–2561
  111. Morandi F, Chiesa S, Bocca P, et al. Tumor mRNA-transfected dendritic cells stimulate the generation of CTL that recognize neuroblastoma-associated antigens and kill tumor cells: immunotherapeutic implications. Neoplasia. 2006;8:833–842
  112. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid 34 tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61:8513–8519
  113. Caruso DA, Orme LM, Amor GM, et al. Results of a phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with stage 4 neuroblastoma. Cancer. 2005;103:1280–1291
  114. Castriconi R, Dondero A, Augugliaro R, et al. Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci USA. 2004;101:12640–12645
  115. Castriconi R, Dondero A, Cilli M, et al. Human NK cell infusions prolong survival of metastatic human neuroblastoma-bearing NOD/scid mice. Cancer Immunol Immunother. 2007;56:1733–1742
  116. Castriconi R, Dondero A, Corrias MV, et al. Natural killer cell-mediated killing of freshly isolated neuroblastoma cells: critical role of DNAX accessory molecule-1-poliovirus receptor interaction. Cancer Res. 2004;64:9180–9184
  117. Venstrom J, Zheng J, Noor N, et al. KIR and HLA genotypes are associated with disease progression and survival following autologous hematopoietic stem cell transplantation for high-risk neuroblastoma. Clin Can Res. 2009;15:7330–7334
  118. Pule MA, Savoldo B, Myers GD, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14:1264–1270
  119. Park JR, Digiusto DL, Slovak M, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15:825–833
  120. Rousseau RF, Haight AE, Hirschmann-Jax C, et al. Local and systemic effects of an allogeneic tumor cell vaccine combining transgenic human lymphotactin with interleukin-2 in patients with advanced or refractory neuroblastoma. Blood. 2003;101:1718–1726
  121. Russell HV, Strother D, Mei Z, et al. Phase I trial of vaccination with autologous neuroblastoma tumor cells genetically modified to secrete IL-2 and lymphotactin. J Immunother. 2007;30:227–233
  122. Russell HV, Strother D, Mei Z, et al. A phase 1/2 study of autologous neuroblastoma tumor cells genetically modified to secrete IL-2 in patients with high-risk neuroblastoma. J Immunother. 2008;31:812–819
  123. Zeytin H, Tripathi PK, Bhattacharya-Chatterjee M, Foon KA, Chatterjee SK. DNA vaccine based on the structure of an anti idiotype antibody mimicking the GD2 ganglioside. Proc Am Assoc Cancer Res. 1997;38:399
  124. Yu A. Promising results of a pilot trial of a GD2 directed anti-idiotypic antibody as a vaccine for high risk neuroblastoma. Proc ANR Meet (abs), 2004.
  125. Ragupathi G, Livingston P, Hood C, et al. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-2. Clin Canc Res. 2003;9:5214–5220
  126. Livingston PO, Adluri S, Helling F. Phase 1 trial of immunological adjuvant QS-21 with a GM2 ganglioside-keyhole limpet haemocyanin conjugate vaccine in patients with malignant melanoma. Vaccines. 1994;12:1275–1280
  127. DuBois SG, Messina J, Maris JM, et al. Hematologic toxicity of high-dose iodine-35 131-metaiodobenzylguanidine therapy for advanced neuroblastoma. J Clin Oncol. 2004;22:2452–2460
  128. Matthay KK, Huberty J, Hawkins RA, et al. 131-I-MIBG double infusion with autologous stem cell transplant (ASCT) for neuroblastoma: a new approaches to neuroblastoma therapy (NANT) study. In: Advances in neuroblastoma research: eleventh conference. J Clin Oncol 2009;27:1020–5.
  129. Corbett R, Olliff J, Fairley N, et al. A prospective comparison between magnetic resonance imaging, meta-iodobenzylguanidine scintigraphy and marrow histology/cytology in neuroblastoma. Eur J Cancer. 1991;27:1560–1564
  130. Yanik GA, Levine JE, Matthay KK, et al. Pilot study of iodine-131-metaiodobenzylguanidine in combination with myeloablative chemotherapy and autologous stem-cell support for the treatment of neuroblastoma. J Clin Oncol. 2002;20:2142–2149
  131. Miano M, Garaventa A, Pizzitola MR, et al. Megatherapy combining I(131) metaiodobenzylguanidine and high-dose chemotherapy with haematopoietic progenitor cell rescue for neuroblastoma. Bone Marrow Transplant. 2001;27:571–574
  132. Fitzgerald PA, Goldsby RE, Huberty JP, et al. Malignant pheochromocytomas and paragangliomas: a phase II study of therapy with high-dose 131I-metaiodobenzylguanidine (131I-MIBG). Ann N Y Acad Sci. 2006;1073:465–490
  133. Osajima-Hakomori Y, Miyake I, Ohira M, Nakagawara A, Nakagawa A, Sakai R. Biological role of anaplastic lymphoma kinase in neuroblastoma. Am J Pathol. 2005;167:213–222
  134. Lamant L, Pulford K, Bischof D, et al. Expression of the ALK tyrosine kinase gene in neuroblastoma. Am J Pathol. 2000;156:1711–1721
  135. Mosse YP, Laudenslager M, Longo L, et al. Identification of ALK as a major familial neuroblastoma predisposition gene. Nature. 2008;455:930–935
  136. Caren H, Abel F, Kogner P, Martinsson T. High incidence of DNA mutations and gene amplifications of the ALK gene in advanced sporadic neuroblastoma tumours. Biochem J. 2008;416:153–159
  137. George RE, Sanda T, Hanna M, et al. Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature. 2008;455:975–978
  138. Scala S, Wosikowski K, Giannakakou P, et al. Brain-derived neurotrophic factor protects neuroblastoma cells from vinblastine toxicity. Cancer Res. 1996;56:3737–3742
  139. Schramm A, Schulte JH, Astrahantseff K, et al. Biological effects of TrkA and TrkB receptor signaling in neuroblastoma. Cancer Lett. 2005;228:143–153
  140. Belkov VM, Krynetski EY, Schuetz JD, et al. Reduced folate carrier expression in acute lymphoblastic leukemia: a mechanism for ploidy but not lineage differences in methotrexate accumulation. Blood. 1999;93:1643–1650
  141. Sartelet H, Oligny LL, Vassal G. AKT pathway in neuroblastoma and its therapeutic implication. Expert Rev Anticancer Ther. 2008;8:757–769
  142. Coulter DW, Blatt J, D’Ercole AJ, Moats-Staats BM. IGF-I receptor inhibition combined with rapamycin or temsirolimus inhibits neuroblastoma cell growth. Anticancer Res. 2008;28:1509–1516
  143. Kolb EA, Gorlick R, Houghton PJ, et al. Initial testing (stage 1) of a monoclonal antibody (SCH 717454) against the IGF-1 receptor by the pediatric preclinical testing program. Pediatr Blood Cancer. 2008;50:1190–119736
  144. Tweddle DA, Pearson AD, Haber M, et al. The p53 pathway and its inactivation in neuroblastoma. Cancer Lett. 2003;197:93–98
  145. Tweddle DA, Malcolm AJ, Cole M, Pearson AD, Lunec J. P53 cellular localization and function in neuroblastoma: evidence for defective G(1) arrest despite WAF1 induction in MYCN-amplified cells. Am J Pathol. 2001;158:2067–2077
  146. Chesler L, Goldenberg DD, Collins R, et al. Chemotherapy-induced apoptosis in a transgenic model of neuroblastoma proceeds through p53 induction. Neoplasia. 2008;10:1268–1274
  147. Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 2001;61:8–13
  148. Carr J, Bell E, Pearson AD, et al. Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. Cancer Res. 2006;66:2138–2145
  149. Yu Q. Restoring p53-mediated apoptosis in cancer cells: new opportunities for cancer therapy. Drug Resist Updat. 2006;9:19–25
  150. Shankar SL, Krupski M, Parashar B, et al. UCN-01 alters phosphorylation of Akt and GSK3beta and induces apoptosis in six independent human neuroblastoma cell lines. J Neurochem. 2004;90:702–711
  151. Condorelli F, Gnemmi I, Vallario A, Genazzani AA, Canonico PL. Inhibitors of histone deacetylase (HDAC) restore the p53 pathway in neuroblastoma cells. Br J Pharmacol. 2008;153:657–668
  152. Coffey DC, Kutko MC, Glick RD, et al. The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid. Cancer Res. 2001;61:3591–3594
  153. Coffey DC, Kutko MC, Glick RD, et al. Histone deacetylase inhibitors and retinoic acids inhibit growth of human neuroblastoma in vitro. Med Pediatr Oncol. 2000;35:577–581
  154. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000;6:1900–1908
  155. Ribatti D, Raffaghello L, Marimpietri D, et al. Fenretinide as an anti-angiogenic agent in neuroblastoma. Cancer Lett. 2003;197:181–184
  156. Kaicker S, McCrudden KW, Beck L, et al. Thalidomide is anti-angiogenic in a xenograft model of neuroblastoma. Int J Oncol. 2003;23:1651–1655
  157. Kim ES, Serur A, Huang J, et al. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Proc Natl Acad Sci USA. 2002;99:11399–11404
  158. Bender JL, Adamson PC, Reid JM, et al. Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a children’s oncology group study. J Clin Oncol. 2008;26:399–405
  159. Peng H, Sohara Y, Moats RA, et al. The activity of zoledronic acid on neuroblastoma bone metastasis involves inhibition of osteoclasts and tumor cell survival and proliferation. Cancer Res. 2007;67:9346–9355
  160. Opel D, Poremba C, Simon T, Debatin KM, Fulda S. Activation of Akt predicts poor outcome in neuroblastoma. Cancer Res. 2007;67:735–745
  161. LoPiccolo J, Blumenthal GM, Bernstein WB, Dennis PA. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Updat. 2008;11:32–50
  162. Modak S, Kramer K, Gultekin SH, Guo HF, Cheung NK. Monoclonal antibody 8H9 targets a novel cell surface antigen expressed by a wide spectrum of human solid tumors. Cancer Res. 2001;61:4048–4054
  163. Kramer K, Smith-Jones P, Humm J, et al. Therapy of central nervous system and leptomeningeal cancers with intra-Ommaya radioiodine labeled 3F8: preliminary results of a phase II study. Proc AACR, 2007:LB–L7.
  164. Valteau-Couanet D, Michon J, Boneu A, et al. Results of induction chemotherapy in children older than 1 year with a stage 4 neuroblastoma treated with the NB 97 French society of pediatric oncology (SFOP) protocol. J Clin Oncol. 2005;23:532–540
  165. Hobbie WL, Moshang T, Carlson CA, et al. Late effects in survivors of tandem peripheral blood stem cell transplant for high-risk neuroblastoma. Pediatr Blood Cancer. 2008;51:679–683
  166. Brodeur GM, Pritchard J, Berthold F, et al. Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol. 1993;11:1466–1477

PII: S0305-7372(10)00026-5

doi: 10.1016/j.ctrv.2010.02.006

Cancer Treatment Reviews
Volume 36, Issue 4 , Pages 307-317 , June 2010

Article Tools

* Image Usage & Resolution